Related references
Note: Only part of the references are listed.EAACI Biologicals Guidelines-Recommendations for severe asthma
Ioana Agache et al.
ALLERGY (2021)
Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation
Katrien Eger et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Benralizumab after sub-optimal response to mepolizumab in severe eosinophilic asthma
Joanne E. Kavanagh et al.
ALLERGY (2021)
Development of a Tool to Measure the Clinical Response to Biologic Therapy in Uncontrolled Severe Asthma: The FEV1, Exacerbations, Oral Corticosteroids, Symptoms Score
Luis Perez de Llano et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)
Expert Consensus on the Tapering of Oral Corticosteroids for the Treatment of Asthma A Delphi Study
Carey M. Suehs et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2021)
How can we minimise the use of regular oral corticosteroids in asthma?
Arnaud Bourdin et al.
EUROPEAN RESPIRATORY REVIEW (2020)
Switch from IL-5 to IL-5-Receptor α Antibody Treatment in Severe Eosinophilic Asthma
Nora Drick et al.
JOURNAL OF ASTHMA AND ALLERGY (2020)
Effect of mepolizumab in severe eosinophilic asthma according to omalizumab eligibility
Marc Humbert et al.
RESPIRATORY MEDICINE (2019)
Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma
Klaus F. Rabe et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical and economic burden of severe asthma: A French cohort study
Clementine Nordon et al.
RESPIRATORY MEDICINE (2018)
Adverse events profile of oral corticosteroids among asthma patients in the UK: cohort study with a nested case-control analysis
Marlene Bloechliger et al.
RESPIRATORY RESEARCH (2018)
Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma
Parameswaran Nair et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial
Eugene R. Bleecker et al.
LANCET (2016)
Benralizumab, an anti-interleukin-5 receptor a monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial
J. Mark FitzGerald et al.
LANCET (2016)
Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic Asthma
Elisabeth H. Bel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Mepolizumab Treatment in Patients with Severe Eosinophilic Asthma
Hector G. Ortega et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Using and Reporting the Delphi Method for Selecting Healthcare Quality Indicators: A Systematic Review
Rym Boulkedid et al.
PLOS ONE (2011)
Using the Delphi Technique to Determine Which Outcomes to Measure in Clinical Trials: Recommendations for the Future Based on a Systematic Review of Existing Studies
Ian P. Sinha et al.
PLOS MEDICINE (2011)
Shared Treatment Decision Making Improves Adherence and Outcomes in Poorly Controlled Asthma
Sandra R. Wilson et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)